AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18343177 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 1
Study 15963077 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 600 mg/day
Number of subjects: 90
Study 15963077 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 800 mg/day
Number of subjects: 90
Study 15963077 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 1200 mg/day
Number of subjects: 90
Study 12647599 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (12.5 to 25 mg/day; n = 15,255)
Number of subjects: 33357
Study 12647599 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5 to 10 mg/day; n = 9,048)
Number of subjects: 33357
Study 12647599 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10 to 40 mg; n = 9,054)
Number of subjects: 33357
Study 12647599 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 33357
Study 12647599 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 33357
Study 10497444 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (5-20 micrograms/ml)
Number of subjects: 24
Study 10497444 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (10-20 micrograms/ml)
Number of subjects: 24
Study 10497444 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 24
Study 10497444 — intervention group
Group type: COMPARATOR
Intervention: Asthmatics
Number of subjects: 24
Study 8712268 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprotected sex with female sex workers
Number of subjects: 600
Study 8712268 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual experience and number of partners
Number of subjects: 600
Study 8712268 — intervention group
Group type: EXPERIMENTAL
Intervention: Intercourse before 18 years of age
Number of subjects: 600
Study 8712268 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of partners
Number of subjects: 600
Study 8712268 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use with female sex workers
Number of subjects: 600
Study 30907159 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based physiotherapy intervention (twice-weekly sessions)
Number of subjects: 11
Study 30907159 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based physiotherapy intervention
Number of subjects: 11
Study 30257783 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-navigated total knee arthroplasties
Number of subjects: 30
Study 30257783 — intervention group
Group type: COMPARATOR
Intervention: Conventional total knee replacements
Number of subjects: 30
Study 27803231 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose dual-antibiotic impregnated cement
Number of subjects: 848
Study 27803231 — intervention group
Group type: COMPARATOR
Intervention: Low dose single-antibiotic impregnated cement
Number of subjects: 848
Study 27803231 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 848
Study 24848642 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperlongumin (PL)
Number of subjects: 4
Study 24848642 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐phenylethyl isothiocyanate (PEITC)
Number of subjects: 4
Study 24848642 — intervention group
Group type: COMPARATOR
Intervention: Lactic acidosis (LA)
Number of subjects: 4
Study 24848642 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐buthionine sulfoximine (L‐BSO, 20 μM)
Number of subjects: 4
Study 22324565 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance by a supportive significant other (SSO) during combined behavioral intervention (CBI) sessions
Number of subjects: 776
Study 22324565 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of an SSO during drink refusal training session
Number of subjects: 776
Study 22324565 — intervention group
Group type: EXPERIMENTAL
Intervention: SSO attendance at communication training session
Number of subjects: 776
Study 21132610 — intervention group
Group type: EXPERIMENTAL
Intervention: Interspinous stand-alone spacer insertion (Aperius (®); Medtronic)
Number of subjects: 36
Study 21132610 — intervention group
Group type: COMPARATOR
Intervention: Microsurgical bilateral operative decompression
Number of subjects: 36
Study 21132610 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 21132610 — intervention group
Group type: EXPERIMENTAL
Intervention: Interspinous stand-alone spacer insertion
Number of subjects: 36
Study 17046182 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate discontinuation of hormone therapy (n=35)
Number of subjects: 70
Study 17046182 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapered discontinuation of hormone therapy (n=35)
Number of subjects: 70
Study 16390401 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (amBisome) 50 mg daily
Number of subjects: 83
Study 16390401 — intervention group
Group type: COMPARATOR
Intervention: Conventional amphotericin B (amB) 15 mg daily
Number of subjects: 83
Study 12926181 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term immunotherapy with TA tree pollen and the immunoadjuvant monophosphoryl Lipid A
Number of subjects: 12
Study 12926181 — intervention group
Group type: COMPARATOR
Intervention: Placebo suspension containing 2% tyrosine
Number of subjects: 12
Study 9426829 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-10
Number of subjects: 0
Study 8535656 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of disease‐modifying antirheumatic drugs (DMARDs)
Number of subjects: 0
Study 8535656 — intervention group
Group type: COMPARATOR
Intervention: Single DMARDs
Number of subjects: 0
Study 8535656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2650722 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (100 mg/m2) monthly for up to 5 cycles
Number of subjects: 88
Study 2650722 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin (400 mg/m2) monthly for up to 5 cycles
Number of subjects: 88
Study 882723 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg isoproterenol sulfate
Number of subjects: 13
Study 882723 — intervention group
Group type: COMPARATOR
Intervention: Placebo (freon propellent alone)
Number of subjects: 13
Study 31095318 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in interprofessional shared decision-making (SDM)
Number of subjects: 309
Study 31095318 — intervention group
Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 309
Study 30052699 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly self-incentivizing (n = 44)
Number of subjects: 159
Study 30052699 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly self-incentivizing (n = 50)
Number of subjects: 159
Study 30052699 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 65)
Number of subjects: 159
Study 28739559 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based postnatal health check plus nurse-moderated Internet-based group support
Number of subjects: 819
Study 28739559 — intervention group
Group type: COMPARATOR
Intervention: Standard care consisting of postnatal home-based support provided by a community nurse
Number of subjects: 819
Study 25746057 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 160
Study 25746057 — intervention group
Group type: COMPARATOR
Intervention: Control (no sevoflurane)
Number of subjects: 160
Study 24138608 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based employment services at implementation sites
Number of subjects: 801
Study 24138608 — intervention group
Group type: EXPERIMENTAL
Intervention: Service visit
Number of subjects: 801
Study 24138608 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement approach
Number of subjects: 801
Study 24138608 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline surveys
Number of subjects: 801
Study 20512497 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic intervention with fermented milk prepared with Lactobacillus GG and L. gasseri TMC0356 for 10 weeks during pollen spread
Number of subjects: 29
Study 20512497 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic intervention with fermented milk prepared with Lactobacillus GG and L. gasseri TMC0356
Number of subjects: 29
Study 19332233 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum phosphorus >3.9 mg/dL
Number of subjects: 950
Study 19332233 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline calcium‐phosphorus product >36.8 mg(2)/dL(2)
Number of subjects: 950
Study 19332233 — intervention group
Group type: EXPERIMENTAL
Intervention: Average serum phosphorus (time-dependent model)
Number of subjects: 950
Study 16846734 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,250 mg/m(2) Days 1 and 8 and paclitaxel 175 mg/m(2) as a 3‐h infusion on Day 1 (GP1)
Number of subjects: 210
Study 16846734 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m(2) Days 1 and 8 and paclitaxel 100 mg/m(2) as a 1‐h infusion on Days 1 and 8 (GP2)
Number of subjects: 210
Study 16846734 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m(2) Days 1 and 8 and docetaxel 40 mg/m(2) as a 1‐h infusion on Days 1 and 8 (GD)
Number of subjects: 210
Study 12631049 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich drinks (2 x 400 ml)
Number of subjects: 48
Study 12631049 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate with peptide drinks (2 x 400 ml)
Number of subjects: 48
Study 12631049 — intervention group
Group type: COMPARATOR
Intervention: Fasting overnight with only water
Number of subjects: 48
Study 11205196 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative serum PIIINP concentration
Number of subjects: 56
Study 11205196 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month serum PIIINP concentration
Number of subjects: 56
Study 11205196 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month serum PIIINP concentration
Number of subjects: 56
Study 11205196 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month serum CA125 concentration
Number of subjects: 56
Study 11205196 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month serum CA125 concentration
Number of subjects: 56
Study 11205196 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in serum CA125 concentration
Number of subjects: 56
Study 11205196 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative PIIINP and 12-month CA125 concentrations
Number of subjects: 56
Study 9200198 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGI + DBA
Number of subjects: 0
Study 9200198 — intervention group
Group type: EXPERIMENTAL
Intervention: RMGI
Number of subjects: 0
Study 9200198 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR
Number of subjects: 0
Study 9200198 — intervention group
Group type: EXPERIMENTAL
Intervention: GI
Number of subjects: 0
Study 9200198 — intervention group
Group type: EXPERIMENTAL
Intervention: ZP
Number of subjects: 0
Study 9200198 — intervention group
Group type: COMPARATOR
Intervention: PC
Number of subjects: 0
Study 9200198 — intervention group
Group type: COMPARATOR
Intervention: ZOE
Number of subjects: 0
Study 1608114 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidrug chemotherapy regimens
Number of subjects: 170
Study 3919752 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 mg/kg of lormetazepam
Number of subjects: 20
Study 3919752 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg of flunitrazepam
Number of subjects: 20
Study 3919752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29446084 — intervention group
Group type: EXPERIMENTAL
Intervention: PP1M (50-150 mg-eq)
Number of subjects: 1429
Study 29446084 — intervention group
Group type: EXPERIMENTAL
Intervention: PP3M
Number of subjects: 1429
Study 29446084 — intervention group
Group type: COMPARATOR
Intervention: PP1M
Number of subjects: 1429
Study 26990723 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load group (LLG)
Number of subjects: 27
Study 26990723 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-load group (MLG)
Number of subjects: 27
Study 26990723 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 27
Study 24834792 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle changes (diet and exercise) during pregnancy
Number of subjects: 360
Study 24834792 — intervention group
Group type: COMPARATOR
Intervention: Routine pregnancy care (Control)
Number of subjects: 360
Study 24834792 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational weight gain ≤9 kg
Number of subjects: 360
Study 24834792 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational weight gain >9 kg
Number of subjects: 360
Study 24834792 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding initiation
Number of subjects: 360
Study 24834792 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum weight retention ≤5 kg
Number of subjects: 360
Study 24834792 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum weight retention >5 kg
Number of subjects: 360
Study 22436170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondasetron 8 mg iv
Number of subjects: 80
Study 22436170 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 5 mg iv
Number of subjects: 80
Study 20162580 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetoencephalography (MEG) analysis of S1 and M1 areas
Number of subjects: 0
Study 20162580 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of S1-M1 dynamic recruitment with thalamic volume
Number of subjects: 0
Study 18955908 — intervention group
Group type: EXPERIMENTAL
Intervention: Viewing point-light dot animations of biological motion (specifics on dosage and duration not available)
Number of subjects: 2
Study 16779172 — intervention group
Group type: EXPERIMENTAL
Intervention: CoViSTA system (Computerized Vital Sign Transfer Application)
Number of subjects: 60
Study 16779172 — intervention group
Group type: COMPARATOR
Intervention: Current practice of collecting vital signs
Number of subjects: 60
Study 12123126 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 26
Study 12123126 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 26
Study 12123126 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MMF and Azathioprine
Number of subjects: 26
Study 10220643 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary cotinine
Number of subjects: 5164
Study 10220643 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of cigarettes smoked per day
Number of subjects: 5164
Study 8558750 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial bolus dose of 30% rt-PA (41.4 mg) followed by infusion over 60 min
Number of subjects: 82
Study 8558750 — intervention group
Group type: COMPARATOR
Intervention: Initial bolus dose of 10% rt-PA (41.4 mg) followed by infusion over 60 min
Number of subjects: 82
Study 2142189 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in a stroke club (experimental)
Number of subjects: 38
Study 2142189 — intervention group
Group type: COMPARATOR
Intervention: No participation in a stroke club (control)
Number of subjects: 38
Study 6452463 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin, 1.5% topical solution (n = 127)
Number of subjects: 253
Study 6452463 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (n = 126)
Number of subjects: 253
Study 30304644 — intervention group
Group type: EXPERIMENTAL
Intervention: REACH-HF intervention (facilitated self-care and home-based cardiac rehabilitation programme)
Number of subjects: 216
Study 30304644 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 216
Study 30170024 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogels (Level 1 - syrup, Level 2 - custard, Level 3 - pudding)
Number of subjects: 30
Study 30170024 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 30
Study 28974250 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodynamics
Number of subjects: 0
Study 28974250 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study 26048602 — intervention group
Group type: COMPARATOR
Intervention: Conventional occupational therapy (5 times per week)
Number of subjects: 27
Study 26048602 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional occupational therapy (3 times per week) + differential training-based occupational therapy (2 times per week)
Number of subjects: 27
Study 24565295 — intervention group
Group type: EXPERIMENTAL
Intervention: Group HDO (ondansetron 8 mg, dexamethasone 8 mg, haloperidol 2 mg)
Number of subjects: 90
Study 24565295 — intervention group
Group type: COMPARATOR
Intervention: Group O (ondansetron 8 mg)
Number of subjects: 90
Study 21059869 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% FGF-2
Number of subjects: 253
Study 21059869 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% FGF-2
Number of subjects: 253
Study 21059869 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% FGF-2
Number of subjects: 253
Study 21059869 — intervention group
Group type: COMPARATOR
Intervention: Vehicle alone (0% FGF-2)
Number of subjects: 253
Study 18774696 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 60
Study 18774696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 17208898 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC/3TC/ZDV (300/150/300 mg) and TDF (300 mg) once daily
Number of subjects: 123
Study 12712083 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 68
Study 12712083 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution placebo
Number of subjects: 68
Study 10834422 — intervention group
Group type: EXPERIMENTAL
Intervention: Injected liquid silicone (6 injections of 0.2 ml)
Number of subjects: 28
Study 10834422 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline injections)
Number of subjects: 28
Study 9663840 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg b.d. plus clarithromycin 500 mg b.d.
Number of subjects: 122
Study 9663840 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg b.d. plus amoxycillin 1000 mg b.d.
Number of subjects: 122
Study 8130290 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized instructional program
Number of subjects: 42
Study 8130290 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-instructional program
Number of subjects: 42
Study 3698813 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine
Number of subjects: 0
Study 3698813 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 3698813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30992480 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional continuous glucose monitoring (p-CGM) with SMBG
Number of subjects: 68
Study 30992480 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring of blood glucose (SMBG) alone
Number of subjects: 68
Study 29327449 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT + SRP
Number of subjects: 60
Study 29327449 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 60
Study 26814305 — intervention group
Group type: EXPERIMENTAL
Intervention: Group assessment format (supported self-assessment)
Number of subjects: 211
Study 26814305 — intervention group
Group type: COMPARATOR
Intervention: Individual assessment
Number of subjects: 211
Study 26437939 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning condition
Number of subjects: 160
Study 26437939 — intervention group
Group type: COMPARATOR
Intervention: Education-only control condition
Number of subjects: 160
Study 22116795 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES training
Number of subjects: 20
Study 22116795 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 20
Study 20543741 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing rest intervals (DIs)
Number of subjects: 20
Study 20543741 — intervention group
Group type: COMPARATOR
Intervention: Constant rest intervals (CIs)
Number of subjects: 20
Study 18758356 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural methylprednisolone 40 mg
Number of subjects: 200
Study 18758356 — intervention group
Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 200
Study 15899442 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafilcon A (Focus Night & Day)
Number of subjects: 100
Study 15899442 — intervention group
Group type: COMPARATOR
Intervention: Etafilcon A (Acuvue)
Number of subjects: 100
Study 12571466 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.6 mg/kg per day for 4 consecutive days once monthly for 6 months, n = 15)
Number of subjects: 23
Study 12571466 — intervention group
Group type: COMPARATOR
Intervention: IVIg (800 mg/kg intravenously once monthly for 6 months, n = 8)
Number of subjects: 23
Study 10850589 — intervention group
Group type: EXPERIMENTAL
Intervention: ATG Fresenius S (9 mg/kg)
Number of subjects: 76
Study 10850589 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ATG)
Number of subjects: 76
Study 8577016 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured lipids (1.0 g/kg per day in part 1, 1.5 g/kg per day in part 2)
Number of subjects: 0
Study 8577016 — intervention group
Group type: COMPARATOR
Intervention: Long-chain triglycerides (LCT) (1.0 g/kg per day in part 1, 1.5 g/kg per day in part 2)
Number of subjects: 0
Study 3155240 — intervention group
Group type: COMPARATOR
Intervention: No treatment for the first 10 days of the disease
Number of subjects: 138
Study 3155240 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin treatment
Number of subjects: 138
Study 3155240 — intervention group
Group type: EXPERIMENTAL
Intervention: High doses of steroids
Number of subjects: 138
Study 3155240 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 138
Study 1210468 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (intraarticular treatment)
Number of subjects: 0
Study 1210468 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (local applications)
Number of subjects: 0
Study 31195825 — intervention group
Group type: EXPERIMENTAL
Intervention: IN.PACT Admiral DCB
Number of subjects: 331
Study 31195825 — intervention group
Group type: COMPARATOR
Intervention: PTA
Number of subjects: 331
Study 28522351 — intervention group
Group type: EXPERIMENTAL
Intervention: Early supplemental parenteral nutrition (PN)
Number of subjects: 1440